What are you looking for?

Library
Poster
Full Title

Lung Function In A/J Mice Following Sub-Chronic Cigarette Smoke Exposure Patterns Of Emphysematous And Fibrotic Changes


Authored by  J Pype, E Van Miert, K Meurrens, M Peck, P Vanscheeuwijck

Presented at 5th International Multidisciplinary Meeting On Chronic Obstructive Pulmonary Disease     

Abstract

Airflow limitation due to small airway diseases and emphysema is a defining feature of COPD. We investigated lung function in female A/J mice exposed to fresh air or MS from the reference cigarette 2R4F for 2, 3, or 4 x 1 hour/day, 5 days/week at 750 µg total particulate matter (TPM)/L for 3 and 5 months. Respiratory mechanics were determined in anesthetized mice (10/group) using a computer-controlled small animal ventilator (Flexivent). At 3 months, no significant increase in tissue elastance (HTIS) was found, while at 5 months HTIS was significantly increased at all smoke doses (14.6±1.2, 19.1±5.9, 18.9±2.0 and 19.4±1.8 for 0, 1500, 2250, and 3000 µg TPM/(L x day), respectively. For all MS-exposed mice at 3 and 5 months, maximal lung volume (at 30 cm H2O) was significantly increased (30.3±3.2 vs 58.5±4.2 ml/Kg, Sham vs 3000 µg TPM/(L x day) group at 5 months) and the maximal airway pressure at total lung capacity was significantly decreased (40.4.±4.4 vs 24.9±4.1 cm H2O, sham vs 3000 µg TPM/(L x day) group at 5 months). Sub-chronic MS exposure in A/J mice resulted in time- and dose-dependent changes in lung function parameters, similar to changes observed in bleomycin (fibrosis)- and elastase (emphysema)-treated mice. 

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced Risk Products (“RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.